Cargando…
Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer
PURPOSE/OBJECTIVE(S): After taxane and anthracycline failure, no standard chemotherapy regimen is established in metastatic breast cancer (MBC). Capecitabine and cisplatin (XP) combination shows promising results in gastrointestinal cancer, but there are relatively scarce data in MBC. We reviewed th...
Autores principales: | Lee, Jieun, Kim, Hyun Ho, Ro, Sang Mi, Yang, Ji Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325186/ https://www.ncbi.nlm.nih.gov/pubmed/28234911 http://dx.doi.org/10.1371/journal.pone.0171605 |
Ejemplares similares
-
Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma
por: Park, Se Hoon, et al.
Publicado: (2006) -
Comparison of the Efficacy between Gemcitabine-Cisplatin and Capecitabine-Cisplatin Combination Chemotherapy for Advanced Biliary Tract Cancer
por: Lee, Jieun, et al.
Publicado: (2015) -
Phase II trial of capecitabine plus modified cisplatin (mXP) as first-line therapy in Japanese patients with metastatic gastric cancer (KSCC1104)
por: Satake, Hironaga, et al.
Publicado: (2016) -
Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients
por: Zhang, Pin, et al.
Publicado: (2016) -
Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer
por: Chen, Pei-Hsin, et al.
Publicado: (2021)